Daewoong reveales Ph 3 data of novel gastroesophageal reflux disease agent
Singapore, May 11 -- Daewoong Pharmaceutical (Daewoong) from South Korea unveiled for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10% posters of all American Gastroenterological Association (AGA) abstracts selected for poster presentation and selected as a Poster of Distinction for presentation during Digestive Disease Week.
Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which reversibly blocks the proton pump that secretes gastric acids located in the cannalicular membrane. It is a next-generation of proton pump inhibitors (PPI), which are widely use...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.